黑人与白人血友病A患者的抗FVIII抗体:F8单倍型是否起作用?
本研究用多重荧光免疫分析法检测394例血友病A患者(188例黑人、206例白人)血浆抗FVIII抗体滴度,并分析其与重组全长H1、H2及B结构域缺失型H1/H2、H3/H5、H4 FVIII蛋白的结合。多数患者可检出FVIII反应性抗体,当前有抑制物的患者滴度更高;总抗体及抑制性抗体滴度均与F8单倍型不匹配无关,含D1241E和M2238V多态性的肽段不构成线性B细胞表位;B结构域缺失型FVIII蛋白与血浆抗体的反应性明显强于全长FVIII产物。
要点
- 多数血友病A患者可检出FVIII反应性抗体,当前有抑制物者滴度更高。
- 总抗体及抑制性抗体滴度均与F8单倍型不匹配无关。
- B结构域缺失型FVIII蛋白与血浆抗体反应性明显强于全长FVIII产物。
核心结论
- 总抗体及抑制性抗体滴度均与F8单倍型不匹配无关。
- 含D1241E和M2238V多态性的肽段不构成线性B细胞表位。
- B结构域缺失型FVIII蛋白与血浆抗体反应性明显强于全长FVIII产物,提示B结构域移除可能暴露新的B细胞表位。
研究设计与样本
- 用已建立的多重荧光免疫分析法检测394例血友病A患者血浆抗FVIII抗体滴度,其中188例黑人、206例白人。
- 测定血浆抗体与重组全长H1、H2及B结构域缺失型H1/H2、H3/H5、H4 FVIII蛋白的结合。
- 用发色法测定抑制物滴度,用肽微阵列表征线性B细胞表位。
主要发现
- 多数血友病A患者可检出FVIII反应性抗体,当前有抑制物的患者滴度更高。
- 总抗体及抑制性抗体滴度均与F8单倍型不匹配无关。
- 含D1241E和M2238V多态性的肽段不构成线性B细胞表位。
- 与全长FVIII产物相比,B结构域缺失型FVIII蛋白与血浆抗体的反应性明显更强。
关键数值与推荐
- 抑制物影响25%至30%的重型血友病A患者。
- 80%至90%的白人人群携带H1单倍型。
- F8单倍型H1至H5由编码FVIII残基1241、2238和484序列变异的非同义单核苷酸多态性定义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most common complication in hemophilia A (HA) treatment, affecting 25% to 30% of patients with severe HA, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation. Inhibitors confer significant pathology on affected individuals and present major complexities in their management. Inhibitors are more common in African American patients, and it has been hypothesized that this is a consequence of haplotype (H)-treatment product mismatch. F8 haplotypes H1 to H5 are defined by nonsynonymous single-nucleotide polymorphisms encoding sequence variations at FVIII residues 1241, 2238, and 484. Haplotypes H2 to H5 are more prevalent in individuals with Black African ancestry, whereas 80% to 90% of the White population has the H1 haplotype. This study used an established multiplex fluorescence immunoassay to determine anti-FVIII antibody titers in plasma from 394 individuals with HA (188 Black, 206 White), measuring their binding to recombinant full-length H1 and H2 and B-domain-deleted (BDD) H1/H2, H3/H5, and H4 FVIII proteins. Inhibitor titers were determined using a chromogenic assay and linear B-cell epitopes characterized using peptide microarrays. FVIII-reactive antibodies were readily detected in most individuals with HA, with higher titers in those with a current inhibitor, as expected. Neither total nor inhibitory antibody titers correlated with F8 haplotype mismatches, and peptides with D1241E and M2238V polymorphisms did not comprise linear B-cell epitopes. Interestingly, compared with the full-length FVIII products, the BDD-FVIII proteins were markedly more reactive with plasma antibodies. The stronger immunoreactivity of BDD-FVIII suggests that B-domain removal might expose novel B-cell epitopes, perhaps through conformational rearrangements of FVIII domains.
引用
- Pratt KP, Gunasekera D, Vir P, et al. Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role? Blood Adv. 2023. PMID: 36459498. doi:10.1182/bloodadvances.2021004909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。